Participants with worse symptoms score and in worsening trajectory group had worse quality of life, higher risk for kidney replacement therapy<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Oct. 31, 2022 (HealthDay News) — Distinct trajectories of chronic kidney disease (CKD) may predict subsequent health outcomes, according to a study published online Oct. 28 in the Clinical Journal of the American Society of Nephrology<\/em>.<\/p>\n Moustapha Faye, M.D., from CHRU-Nancy in France, and colleagues aimed to identify subgroups within the five-year trajectories of symptom evaluation among 2,787 participants with estimated glomerular filtration rate <60 mL\/min\/1.73 m2<\/sup> enrolled in the CKD-Renal Epidemiology and Information Network (CKD-REIN) cohort study from July 2013 to May 2016. Symptoms were assessed annually and 9,121 measures were reported over follow-up.<\/p>\n The researchers found that the prevalence of symptoms ranged from 24 percent for chest pain to 83 percent for fatigue; at least one symptom was reported by 98 percent of participants. Overall, 690 patients initiated kidney replacement therapy (KRT) and 490 died before initiating KRT after a median follow-up of 5.3 years. Two profiles of symptoms trajectories were identified: worse symptom score and worsening trajectory, which was characterized by a low initial symptoms score that worsened more than 10 points over time, a better symptom score, and a stable trajectory (31 and 69 percent, respectively). More risk factors for CKD progression at baseline, worse quality of life, and a higher risk of KRT and death before KRT were seen for participants in the worse symptom score and worsening trajectory group compared with other participants.<\/p>\n “It is possible to actively monitor symptoms and classify patients according to their progression,” Faye said in a statement. “This active symptom tracking will allow early therapeutic interventions to be planned to help manage different symptoms.”<\/p>\n CKD-REIN has been supported by a public-private partnership with several pharmaceutical companies. Several authors disclosed financial ties to these and other pharmaceutical companies.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n